GlassScriptPhysician profile
William J Kelly
NPI 1538185426
$2,527.32
in general payments reported to CMS, 2019-2025
23 companies · $423 in 2025
The $423 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $257 · 2021: $334 · 2022: $405 · 2023: $365 · 2024: $370 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $435.72 | 2019-2025 | Lensx, Rocklatan, Simbrinza |
| Bausch & Lomb Americas INC. | $304.50 | 2022-2025 | Vyzulta, Miebo, Scoutpro Osmolarity System |
| Johnson & Johnson Surgical Vision, INC. | $230.16 | 2019-2023 | Tecnis Simplicity |
| Abbvie INC. | $189.04 | 2022-2025 | |
| Allergan, INC. | $156.60 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $152.52 | 2019-2021 | |
| Astellas Pharma US INC | $128.09 | 2025 | Izervay |
| Kala Pharmaceuticals, INC. | $126.32 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $124.34 | 2019-2023 | |
| Dompe US, INC. | $108.56 | 2019-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $95.20 | 2019-2021 | |
| Oyster Point Pharma, INC. | $89.91 | 2022-2024 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $86.52 | 2024-2025 | Vevye |
| Sight Sciences, INC. | $82.86 | 2020-2025 | Tearcare System, Omni Surgical System, Sion Surgical Instrument |
| Eyevance Pharmaceuticals LLC | $47.77 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $25.54 | 2022 | |
| Amgen INC. | $24.36 | 2024 | Tepezza |
| Apellis Pharmaceuticals, INC. | $23.60 | 2023 | Syfovre |
| Thea Pharma INC. | $22.96 | 2022 | |
| Sun Pharmaceutical Industries INC. | $20.33 | 2020 | |
| Horizon Therapeutics Plc | $19.03 | 2021 | |
| New World Medical,INC. | $18.21 | 2022 | |
| Biotissue Holdings INC. | $15.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.